Across TCGA pan-cancer cohorts, RN7SL864P RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RN7SL864P’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where RN7SL864P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL864P is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.
BRCA and LUAD are the cancer types where RN7SL864P tumor–normal differential expression is most reproducible.